Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.81 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.81 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.81 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740598 | 0.94 | MAPK10 (0.85) | MAPK10MAPK9MAPK8RAB9ANPC1 | |
| SCHEMBL3753376 | 0.93 | MAPK10 (0.70) | MAPK10MAPK9MAPK8RAB9ANPC1 | |
| SCHEMBL4200034 | 0.91 | MAPK10 (0.84) | MAPK10MAPK9MAPK8RAB9ATP53 | |
| SCHEMBL3746727 | 0.90 | MAPK10 (0.79) | MAPK10MAPK9MAPK8RAB9ANPC1 | |
| SCHEMBL15920643 | 0.90 | MAPK9 (0.66) | MAPK10MAPK9MAPK8RAB9ANPC1 | |
| Bentamapimod SCHEMBL2878382 | 0.90 | MAPK10 (1.00) | MAPK10MAPK9MAPK8RAB9ANPC1 | |
| Bentamapimod SCHEMBL29350260 | 0.90 | MAPK10 (1.00) | MAPK10MAPK9MAPK8RAB9ANPC1 | |
| Bentamapimod SCHEMBL29423429 | 0.90 | MAPK10 (1.00) | MAPK10MAPK9MAPK8RAB9ANPC1 | |
| Bentamapimod SCHEMBL30197744 | 0.90 | MAPK10 (1.00) | MAPK10MAPK9MAPK8RAB9ANPC1 | |
| SCHEMBL4198021 | 0.90 | MAPK10 (0.81) | MAPK10MAPK9MAPK8RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | claimed |
| EP-1501828-B1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | claimed |
| US-7314878-B2 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders | LABORATORIES SERONO SA (CH) | 2008-01-01 | — | — | US | claimed |
| EP-1850846-A1 | COMPOSITION COMPRISING A JNK INHIBITOR AND CYCLOSPORIN | Laboratoires Serono SA (CH) | 2007-11-07 | — | — | EP | claimed |
| US-20070088017-A1 | Benzothiazole derivatives for the treatment of diabetes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-04-19 | — | — | US | claimed |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-11-24 | — | — | US | claimed |
| WO-2005097116-A1 | COMPOSITION COMPRISING A JNK INHIBITOR AND CYCLOSPORIN | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-10-20 | — | — | WO | claimed |
| US-7838522-B2 | Benzothiazole formulations and use thereof | ARES TRADING S.A. (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2026802-A2 | JNK INHIBITORS FOR TREATMENT OF SKIN DISEASES | Laboratoires Serono SA (CH) | 2009-02-25 | — | — | EP | disclosed |
| EP-1812072-B1 | BENZOTHIAZOLE FORMULATIONS AND USE THEREOF | ARES TRADING SA (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| EP-1501828-B1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-7314878-B2 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders | LABORATORIES SERONO SA (CH) | 2008-01-01 | — | — | US | disclosed |
| WO-2007141224-A2 | JNK INHIBITORS FOR TREATMENT OF SKIN DISEASES | LABORATOIRES SERONO SA (CH) | 2007-12-13 | — | — | WO | disclosed |
| EP-1812072-A2 | BENZOTHIAZOLE FORMULATIONS AND USE THEREOF | Ares Trading S.A. (CH) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006053882-A2 | BENZOTHIAZOLE FORMULATIONS AND USE THEREOF | ARES TRADING S.A. (CH) | 2006-05-26 | — | — | WO | disclosed |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-11-24 | — | — | US | disclosed |
| EP-1501828-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | Applied Research Systems ARS Holding N.V. (AN) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091249-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | MGLL, MBOAT4, MBOAT1 | MAPK10 3176/4885MAPK9 3960/4885MAPK8 4361/4885 |
| US-20070088017-A1 | Benzothiazole derivatives for the treatment of diabetes | GPR119, GLS2, GLS | MAPK10 3255/4885MAPK9 4264/4885MAPK8 3132/4885 |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | PRDX5, PIR, GRIK5 | MAPK10 3536/4885MAPK9 4329/4885MAPK8 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.